医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Approval for Listing of Shares of Solasia on the Tokyo Stock Exchange Mothers

2017年02月21日 PM03:00
このエントリーをはてなブックマークに追加


 

TOKYO

Solasia Pharma K.K. (Headquarters: Tokyo, Japan, President and CEO: Yoshihiro Arai, hereinafter “Solasia”) an oncology specialized pharmaceutical company developing oncology products for Asian commercial markets, announced today the approval for listing of shares on the Tokyo Stock Exchange (TSE) Mothers.

The scheduled date of the listing of the shares is Friday March 24, 2017, on or after which date the shares will be available for trading on the TSE Mothers.

The proceeds from this offering will be directed primarily to development and commercialization activities, and to execute on the company’s mission of providing “Better medicine for a brighter tomorrow”.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170220005733/en/

CONTACT

for Solasia Pharma K.K.
Rie Toyoda, +81-3-6721-8317
Investors
Relations

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • スミス・ディテクションのBioFlashが空中のCOVID-19を検出可能であることを実証
  • Korean Pet Care Robot PEDDY Gains Popularity to Relieve Pets’ Depression During COVID-19
  • コロナ禍で生じたうつ病をいやす韓国産ペットケアロボット「ペディ」が人気
  • Dr. Reddy’s Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market
  • Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists